MA37963A1 - Protéines de fusion pour traiter un syndrome métabolique - Google Patents

Protéines de fusion pour traiter un syndrome métabolique

Info

Publication number
MA37963A1
MA37963A1 MA37963A MA37963A MA37963A1 MA 37963 A1 MA37963 A1 MA 37963A1 MA 37963 A MA37963 A MA 37963A MA 37963 A MA37963 A MA 37963A MA 37963 A1 MA37963 A1 MA 37963A1
Authority
MA
Morocco
Prior art keywords
treat
fusion proteins
metabolic syndrome
fusion protein
adiposity
Prior art date
Application number
MA37963A
Other languages
English (en)
Inventor
Oliver Boscheinen
Matthias Dreyer
Paul Habermann
Hans-Ludwig Schaefer
Mark Sommerfeld
Thomas Langer
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46888349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37963(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA37963A1 publication Critical patent/MA37963A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une protéine de fusion comprenant au moins un composé fgf-21 (facteur 21 de croissance fibroblastique) et au moins un agoniste de glp-1r (récepteur du peptide 1 de type glucagon), ainsi que des compositions pharmaceutiques, des utilisations médicales et des méthodes de traitement impliquant la protéine de fusion, en particulier dans le domaine du diabète, de la dyslipidémie, de l'obésité et/ou de l'adiposité.
MA37963A 2012-09-07 2013-09-04 Protéines de fusion pour traiter un syndrome métabolique MA37963A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12306072 2012-09-07
PCT/EP2013/068239 WO2014037373A1 (fr) 2012-09-07 2013-09-04 Protéines de fusion pour traiter un syndrome métabolique

Publications (1)

Publication Number Publication Date
MA37963A1 true MA37963A1 (fr) 2018-06-29

Family

ID=46888349

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37963A MA37963A1 (fr) 2012-09-07 2013-09-04 Protéines de fusion pour traiter un syndrome métabolique

Country Status (25)

Country Link
US (3) US20140073563A1 (fr)
EP (1) EP2892919A1 (fr)
JP (1) JP2015533483A (fr)
KR (1) KR20150043505A (fr)
CN (1) CN104736558A (fr)
AR (1) AR092456A1 (fr)
AU (1) AU2013311777B2 (fr)
BR (1) BR112015004734A2 (fr)
CA (1) CA2880929A1 (fr)
CL (1) CL2015000379A1 (fr)
CR (1) CR20150149A (fr)
DO (1) DOP2015000020A (fr)
EA (1) EA201590525A1 (fr)
GT (1) GT201500049A (fr)
HK (1) HK1207097A1 (fr)
IL (1) IL237032A0 (fr)
MA (1) MA37963A1 (fr)
MX (1) MX2015002985A (fr)
PE (1) PE20150648A1 (fr)
PH (1) PH12015500194A1 (fr)
SG (1) SG11201500682WA (fr)
TN (1) TN2015000053A1 (fr)
TW (1) TW201414750A (fr)
UY (1) UY35018A (fr)
WO (1) WO2014037373A1 (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008121563A2 (fr) 2007-03-30 2008-10-09 Ambrx, Inc. Polypeptides fgf-21 modifiés, et leurs utilisations
CN113683705A (zh) 2011-07-01 2021-11-23 恩格姆生物制药公司 用于代谢病症和疾病治疗的组合物、应用和方法
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
CA2892152A1 (fr) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions et methodes de traitement de troubles et maladies metaboliques
CN108888757A (zh) 2012-12-27 2018-11-27 恩格姆生物制药公司 用于调节胆汁酸体内稳态及治疗胆汁酸紊乱和疾病的方法
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN105828878A (zh) 2013-10-28 2016-08-03 恩格姆生物制药公司 癌症模型及相关方法
SG11201606018UA (en) 2014-01-24 2016-08-30 Ngm Biopharmaceuticals Inc Binding proteins and methods of use thereof
WO2015138278A1 (fr) 2014-03-11 2015-09-17 Novartis Ag Méthodes de traitement de troubles métaboliques associés à des lipodystrophies et à des défauts dans la production ou la signalisation de l'insuline
WO2015183890A2 (fr) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Méthodes et compositions pour le traitement de maladies et de troubles métaboliques
WO2015195509A2 (fr) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Procédés et utilisations pour la modulation de l'homéostasie de l'acide biliaire et le traitement de troubles et maladies de l'acide biliaire
CN110179792A (zh) * 2014-07-29 2019-08-30 深圳君圣泰生物技术有限公司 小檗碱盐、熊去氧胆酸盐、相关复方及其制备方法和应用
US10517929B2 (en) 2014-10-23 2019-12-31 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising FGF19 variants
MX2017004947A (es) 2014-10-24 2017-06-29 Bristol Myers Squibb Co Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
WO2016073855A1 (fr) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Procédés de traitement de troubles liés à l'acide biliaire et prédiction de la sensibilité clinique au traitement de troubles liés aux acides biliaires
TWI681966B (zh) * 2014-12-23 2020-01-11 丹麥商諾佛 儂迪克股份有限公司 Ｆｇｆ２１衍生物及其用途
CN110204617B (zh) * 2014-12-31 2023-06-16 天境生物科技(上海)有限公司 含胰高血糖素样肽-1和免疫球蛋白杂合Fc的融合多肽及其用途
WO2017019957A2 (fr) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Protéines de liaison et leurs procédés d'utilisation
KR20180033586A (ko) 2015-08-04 2018-04-03 듀크 유니버시티 전달을 위한 유전적으로 인코딩된 내재적으로 무질서화된 스텔스 중합체 및 이의 이용 방법
KR102670157B1 (ko) * 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
CA3003616C (fr) 2015-11-09 2020-07-28 Ngm Biopharmaceuticals, Inc. Methodes de traitement de troubles associes aux acides biliaires
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
ES2916998T3 (es) 2016-01-13 2022-07-06 Novo Nordisk As Análogos del EGF(A) con sustituyentes de ácidos grasos
JP2019514908A (ja) * 2016-04-29 2019-06-06 ディフェンシン セラピューティクス エーピーエス 肝臓、胆管および膵臓の障害の治療
US11467156B2 (en) 2016-06-01 2022-10-11 Duke University Nonfouling biosensors
EP3502143A4 (fr) 2016-08-19 2020-07-15 Ampsource Biopharma Shanghai Inc. Peptide de liaison pour la construction d'une protéine de fusion
CN106317226B (zh) 2016-08-19 2017-09-05 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
WO2018039557A1 (fr) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Méthodes de traitement de cancers et de tumeurs à médiation assurée par le facteur de croissance des fibroblastes 19
RU2019122785A (ru) 2016-12-22 2021-01-22 Санофи Комбинации соединения на основе fgf21/агониста glp-1r с оптимизированным соотношением активности
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
CN108440668A (zh) * 2017-02-16 2018-08-24 瑞阳(苏州)生物科技有限公司 Fgf21与igf-1的融合蛋白及其应用
US20220127322A1 (en) * 2017-03-14 2022-04-28 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
EP3612637A4 (fr) 2017-04-21 2021-01-27 Yuhan Corporation Procédé de production de protéines à double fonction et ses dérivés
US11554097B2 (en) 2017-05-15 2023-01-17 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
US11680083B2 (en) 2017-06-30 2023-06-20 Duke University Order and disorder as a design principle for stimuli-responsive biopolymer networks
PE20200720A1 (es) 2017-07-19 2020-07-21 Novo Nordisk As Compuestos bifuncionales
MX2020002977A (es) 2017-09-22 2020-11-06 Regeneron Pharma Agonistas de receptor de peptido similar al glucagon tipo 1 y usos de los mismos.
ES2923152T3 (es) * 2017-11-06 2022-09-23 Thena Biotech S R L Proteínas de fusión basadas en ferritina humana y péptidos escindibles por proteasas y su uso como vehículos quimioterapéuticos
CN109836504B (zh) * 2017-11-24 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的多结构域活性蛋白
WO2019119673A1 (fr) 2017-12-19 2019-06-27 北京吉源生物科技有限公司 Cellule souche modifiée par deux gènes et utilisation de cette dernière
CN110028587B (zh) * 2018-01-11 2021-10-08 安源医药科技（上海）有限公司 用于调节血糖和脂质的增效型双功能蛋白
AU2019218147B2 (en) * 2018-02-08 2023-06-08 Sunshine Lake Pharma Co., Ltd. FGF21 variant, fusion protein and application thereof
CN112566655A (zh) * 2018-06-21 2021-03-26 赛诺菲 具有优化的活性比率的fgf21化合物/glp-1r激动剂组合
EP3829622A4 (fr) * 2018-08-02 2022-05-11 Duke University Protéines de fusion à double agoniste
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
CN114853908B (zh) * 2019-05-16 2024-06-07 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
EP4085077A4 (fr) 2019-12-31 2024-01-17 Beijing QL Biopharmaceutical Co., Ltd. Protéines de fusion de glp-1 et de gdf15 et leurs conjugués
WO2021139744A1 (fr) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugués de protéines de fusion du glp-1 et du fgf21
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
CN113735977A (zh) * 2020-05-28 2021-12-03 江苏康缘瑞翱生物医药科技有限公司 rhFGF21融合蛋白、编码其的多核苷酸、包含其组合物及其用途
US20220010021A1 (en) 2020-07-02 2022-01-13 Sanofi FGFR1/KLB Targeting Agonistic Antigen-Binding Proteins and Conjugates Thereof with GLP-1R Agonistic Peptides
US20230357346A1 (en) * 2020-07-10 2023-11-09 Gi Innovation, Inc. Fusion protein including glucagon-like peptide-1 and interleukin-1 receptor antagonist and use thereof
WO2022117044A1 (fr) * 2020-12-03 2022-06-09 Sunshine Lake Pharma Co., Ltd. Polypeptide agoniste du récepteur double glp-1/gcg et sa protéine de fusion
AR125086A1 (es) * 2021-03-23 2023-06-07 Lilly Co Eli Composiciones que contienen análogos de incretina y usos de estas
CN113150172B (zh) * 2021-04-28 2023-09-22 中国药科大学 Glp-1r/gipr双靶点激动剂融合蛋白及其制备方法与应用
WO2022256568A1 (fr) * 2021-06-02 2022-12-08 Arizona Board Of Regents On Behalf Of The University Of Arizona Procédés et compositions pour la localisation de facteurs de croissance
EP4288461A1 (fr) * 2021-07-14 2023-12-13 Beijing QL Biopharmaceutical Co., Ltd. Polypeptides de fusion pour troubles métaboliques
CN113583142A (zh) * 2021-08-20 2021-11-02 赣江中药创新中心 双靶点融合蛋白、编码基因、载体或宿主细胞及其应用与表达和纯化方法
WO2023049631A2 (fr) * 2021-09-09 2023-03-30 Northwestern University Procédés et compositions acellulaires comprenant des hormones thérapeutiques sans marqueur
US20240199728A1 (en) 2022-09-21 2024-06-20 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction
WO2024097875A1 (fr) * 2022-11-02 2024-05-10 Shattuck Labs, Inc. Protéines de fusion pour le traitement de la stéatohépatite non alcoolique
CN117801124A (zh) * 2024-02-29 2024-04-02 天津凯莱英生物科技有限公司 利西那肽前体的融合蛋白及其应用
CN117801125B (zh) * 2024-02-29 2024-05-24 天津凯莱英生物科技有限公司 艾塞那肽前体的融合蛋白及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03219892A (ja) * 1990-01-24 1991-09-27 Kyowa Hakko Kogyo Co Ltd タンパク質の製造法
GB9725556D0 (en) * 1997-12-03 1998-02-04 Ciba Geigy Ag Organic compounds
KR20020007287A (ko) * 1999-01-07 2002-01-26 추후보정 Ｆｃ 융합 단백질로서 항-비만 단백질의 발현 및 이출
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
CN1480466A (zh) * 2002-09-03 2004-03-10 �й������ž�����ҽѧ��ѧԺ����ҽ 一类溶栓抗凝双功能融合蛋白及应用
AP2007003869A0 (en) * 2004-08-03 2007-02-28 Transtech Pharma Inc Rage fusion proteins and methods of use
SG176459A1 (en) * 2005-07-05 2011-12-29 Univ California Polynucleotides encoding isoprenoid modifying enzymes and methods of use thereof
US7625564B2 (en) * 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
WO2008088422A2 (fr) * 2006-10-25 2008-07-24 Amgen Inc. Agents thérapeutiques à base de peptides toxiques
WO2009020802A2 (fr) * 2007-08-03 2009-02-12 Eli Lilly And Company Traitement de l'obésité
US8933197B2 (en) * 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
WO2010091122A1 (fr) * 2009-02-03 2010-08-12 Amunix, Inc. Polypeptides recombinants étendus et compositions les comprenant
CN101993485B (zh) * 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
WO2011047180A1 (fr) * 2009-10-14 2011-04-21 Merrimack Pharmaceuticals, Inc. Agents de liaison bispécifiques qui ciblent la signalisation igf-1r et erbb3, et leurs utilisations
WO2011084808A2 (fr) * 2009-12-21 2011-07-14 Amunix Operating Inc. Compositions de polypeptides bifonctionnels et procédés pour le traitement de maladies métaboliques et cardiovasculaires
EP2460527A1 (fr) * 2010-01-21 2012-06-06 Sanofi Composition pharmaceutique pour le traitement d'un syndrome métabolique
US9266939B2 (en) * 2010-12-27 2016-02-23 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
UY34347A (es) * 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
EP2825557B1 (fr) * 2012-03-16 2017-06-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Fc monomère modifié soluble

Also Published As

Publication number Publication date
WO2014037373A1 (fr) 2014-03-13
UY35018A (es) 2014-03-31
US20160194371A1 (en) 2016-07-07
CL2015000379A1 (es) 2015-06-05
PE20150648A1 (es) 2015-05-25
US20140073563A1 (en) 2014-03-13
AU2013311777B2 (en) 2018-02-01
AR092456A1 (es) 2015-04-22
PH12015500194A1 (en) 2015-04-20
MX2015002985A (es) 2015-06-22
CA2880929A1 (fr) 2014-03-13
EP2892919A1 (fr) 2015-07-15
CN104736558A (zh) 2015-06-24
TW201414750A (zh) 2014-04-16
TN2015000053A1 (en) 2016-06-29
DOP2015000020A (es) 2015-04-15
AU2013311777A1 (en) 2015-03-19
IL237032A0 (en) 2015-03-31
KR20150043505A (ko) 2015-04-22
CR20150149A (es) 2015-05-29
BR112015004734A2 (pt) 2017-11-21
EA201590525A1 (ru) 2015-07-30
JP2015533483A (ja) 2015-11-26
HK1207097A1 (en) 2016-01-22
SG11201500682WA (en) 2015-02-27
GT201500049A (es) 2016-02-15
US20190085043A1 (en) 2019-03-21

Similar Documents

Publication Publication Date Title
MA37963A1 (fr) Protéines de fusion pour traiter un syndrome métabolique
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EA201492053A1 (ru) Белки фактора роста фибробластов 21
MA35458B1 (fr) Variants du facteur de croissance des fibroblastes 21
EA201491161A1 (ru) Фторированные модуляторы рецепторов эстрогенов и их применение
EA201491644A1 (ru) Фармацевтические композиции
MA46219B1 (fr) Composés de co-agonistes du glucagon et du glp-1
EA201270815A1 (ru) Модуляторы рецепторов эстрогена и их применение
EA201201047A1 (ru) Способы и композиции, в которых применяют слитые полипептиды fgf 23
EA201492064A1 (ru) Варианты фактора роста фибробластов 21
EA201101524A1 (ru) Способ и композиция для лечения состояния, связанного с хемосенсорным рецептором
MA38406A1 (fr) Virus de la maladie de newcastle et leurs utilisations
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EA201101709A1 (ru) Полициклические антагонисты рецепторов лизофосфатидной кислоты
EA201591176A1 (ru) Композиции и способы с использованием пептидной метки, связывающейся с гиалуронаном
EA201491530A1 (ru) Модуляторы рецепторов эстрогенов и их применение
EA033373B1 (ru) Композиции на водной основе, предварительно наполненный шприц, их применения и способ доставки гипофукозилированного или нефукозилированного антитела против baffr млекопитающему
EP2560660A4 (fr) Thérapies à base de ligands de récepteurs chimiosensibles
EA201370081A1 (ru) Антитела к cd48 и их применение
EA201270720A1 (ru) Модуляторы рецептора андрогенов и их применение
MY166045A (en) Abeta antibody formulation
EA201690064A1 (ru) Антитела к лектин-подобному рецептору 1 окисленных ldl и способы применения
EA201291167A1 (ru) Замещенные гетероциклилбензилпиразолы и их применение
EA201490790A1 (ru) Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1